AMENDMENTS TO THE CLAIMS

1. (currently amended) An ~~recombinant~~ antibody ~~product~~, comprising the V_H domain of the antibody produced by the hybridoma of ATCC deposit number CRL 8001, wherein the cysteine at position H100A of said V_H domain is substituted with a polar amino acid, wherein said position H100A is according to the Kabat numbering system , wherein said ~~recombinant~~ antibody ~~product~~ comprises the amino acid sequence depicted by SEQ ID NO:2.

Claims 2-3 (cancelled).

4. (currently amended) A method for the production of the ~~recombinant~~ antibody ~~product~~ according to claim 1 ~~or 2~~, characterized by the steps of:

a) obtaining mRNA from freshly subcloned hybridoma cells of ATCC deposit number CRL 8001 and transcription into cDNA,

b) amplifying the cDNA coding for the variable domains of the light and heavy chains by means of PCR,

c) cloning of the cDNA obtained in b) into a vector adapted for site-specific mutagenesis ~~as well as introduction of~~ ,

d) introducing a mutation to the cDNA ~~in said position H100A of the V_H domain, wherein said position H100A is according to the Kabat numbering system~~, wherein said mutation is the substitution of a cysteine with a polar amino acid at position H100A of the V_H domain according to the Kabat numbering system, and

~~d)~~ e) inserting the mutated cDNA obtained in c) in an expression vector and expression in a suitable expression system.

5. (previously amended) The method according to claim 4, wherein the amplifying of step b) uses primers having the nucleotide sequences depicted by SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11 .

6. (previously amended) The method according to claim 4, wherein the vector used in step c) is pCR-Skript SK(+).

7. (previously amended) The method according to claim 4, wherein said cloning

uses a primer comprising the sequence depicted by SEQ ID NO: 7.

Claim 8 (cancelled).

9. (previously amended) The method according to claim 4, wherein the expression takes place in XLl-Blue E. *coli* cells.

12. (previously amended) The method according to claim 5, wherein the vector used in step c) is pCR-Skript SK(+).

13. (previously amended) The method according to claim 5, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

14. (previously amended) The method according to claim 6, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

Claims 15-17 (cancelled).

19. (previously amended) The method according to claim 5, wherein the expression takes place in XLl-Blue E. *coli* cells.

20. (previously amended) The method according to claim 6, wherein the expression takes place in XLl-Blue E. *coli* cells.

21. (previously amended) The method according to claim 7, wherein the expression takes place in XLl-Blue E. *coli* cells.

Claim 22 (cancelled).

23. (previously amended) A peptide comprising the amino acid sequence depicted by SEQ ID NO:2.

24. (previously amended) An antibody comprising the peptide according to Claim 23.

25. (previously amended) A single-chain antibody comprising the peptide according to Claim 23.

26. (previously amended) A bispecific antibody comprising the peptide according to Claim 23.

Claim 27 (cancelled).

28. (new) The antibody of claim 1, wherein said antibody is a monoclonal antibody.

29. (re-presented former dependent claim 2) An antibody, comprising the V_H domain of the antibody produced by the hybridoma of ATCC deposit number CRL 8001, wherein the cysteine at position H100A of said V_H domain is substituted with a serine, wherein said position H100A is according to the Kabat numbering system , wherein said antibody comprises the amino acid sequence depicted by SEQ ID NO:2.